Third time's the charm for $100 million Merrimack IPO after two false starts
This article was originally published in Scrip
Executive Summary
After a false start earlier this year, Cambridge, Massachusetts-based Merrimack Pharmaceuticals Inc. launched on the Nasdaq with an initial public offering of 14.3 million shares of common stock priced at $7 per share to raise $100.1 million on 29 March.